Pharmaceuticals

Biosimilar Monoclonal Antibodies Market Performance Outlook 2026–2030: Revenue to Hit $14.58 Billion at 6.6% CAGR

February 12, 2026February 12, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the biosimilar monoclonal antibodies market from 2026–2035 with trusted insights from The Business Research Company

What total market size is anticipated for the Biosimilar Monoclonal Antibodies Market in 2030?

The biosimilar monoclonal antibodies market has experienced robust expansion in recent years. It is projected to grow from $10.64 billion in 2025 to $11.29 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 6.2%. This historical growth can be attributed to several factors, including the high cost associated with originator biologics, the increasing burden of chronic and autoimmune diseases, the expiration of patents for blockbuster monoclonal antibodies, a rise in healthcare expenditure, and the gradual establishment of regulatory clarity for biosimilars.

The biosimilar monoclonal antibodies market is projected to experience robust expansion over the coming years. By 2030, its value is anticipated to reach $14.58 billion, expanding at a compound annual growth rate (CAGR) of 6.6%. This anticipated growth during the forecast period is fueled by factors such as the broadening of biosimilar pipelines, an escalating need for cost-effective biologic therapies, a rise in approvals within developing markets, continuous improvements in biopharmaceutical manufacturing processes, and encouraging governmental policies supporting biosimilar integration. Key trends during this period are expected to encompass the increasing uptake of economical biosimilar monoclonal antibodies, their expanded application in treating oncology and autoimmune conditions, a growing acceptance among both physicians and patients, the broadening of regulatory approvals across international markets, and a heightened emphasis on enhancing accessibility to biologic treatments.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3412&type=smp

What Drivers Are Influencing Production Trends In The Biosimilar Monoclonal Antibodies Market?

The increasing incidence of autoimmune diseases is expected to propel the growth of the biosimilar monoclonal antibodies market going forward. Autoimmune diseases are disorders where the immune system mistakenly targets and attacks the body’s tissues and organs. This rise in autoimmune diseases is primarily driven by increased environmental triggers, such as pollution and chemicals, which can disrupt immune system balance and promote abnormal immune responses. Biosimilar monoclonal antibodies help address the rising incidence of autoimmune diseases by providing affordable, effective, and widely accessible targeted therapies that manage overactive immune responses in affected patients. For instance, in February 2024 according to the Arthritis Australia is a Australia-based non-profit organization In 2025, an estimated 212,136 males and 362,137 females are projected to have rheumatoid arthritis (RA), with the numbers expected to rise by 2040 to approximately 280,040 males and 479,828 females. Therefore, the rising incidence of autoimmune diseases is driving the growth of the biosimilar monoclonal antibodies market.

Which Segments Are Gaining Traction In The Biosimilar Monoclonal Antibodies Market?

The biosimilar monoclonal antibodies market covered in this report is segmented –

1) By Type: Biopharmaceuticals, Other Types

2) By Compound: Infliximab, Rituximab, Abciximab, Trastuzumab, Adalimumab, Bevacizumab

3) By Application: Chronic & Autoimmune Diseases, Oncology, Other Applications

Subsegments:

1) By Biopharmaceuticals: Monoclonal Antibodies, Recombinant Proteins, Vaccines, Other Biopharmaceuticals

2) By Other Types: Antibody-Drug Conjugates, Fusion Proteins, Biosimilars Of Other Biologics

Which Trends Are Shaping Activity Within The Biosimilar Monoclonal Antibodies Market?

Leading companies in the biosimilar monoclonal antibody market are developing biosimilar versions of the monoclonal antibody to provide more cost-effective options compared to original monoclonal antibody therapies, thus improving healthcare access and affordability. An intravenous formulation describes an antibody preparation designed for direct delivery into the bloodstream through a vein, aiming for a rapid therapeutic effect. For example, in May 2024, Bio-Thera Solutions, a China-based biopharmaceutical firm, along with US-based Biogen Inc., launched TOFIDENCE (tocilizumab-bavi) as an intravenous formulation in the United States. The U.S. Food and Drug Administration had approved TOFIDENCE in September 2023 for addressing moderately to severely active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis. At its introduction, TOFIDENCE is offered in three vial sizes—80 mg/4 mL, 200 mg/10 mL, and 400 mg/20 mL—for intravenous infusion, with subcutaneous formulations slated for future release.

Who Are The Top-Performing Companies In The Biosimilar Monoclonal Antibodies Market In Recent Years?

Major companies operating in the biosimilar monoclonal antibodies market are Pfizer Inc., Novartis AG, AbbVie Inc., Coherus BioSciences, Biocon Limited, Amgen Inc., Boehringer Ingelheim International GmbH, Celltrion Inc., BioXpress Therapeutics SA, Intas Pharmaceuticals Limited, Genor BioPharma Co. Ltd., BIOCAD, Dr. Reddy’s Laboratories Ltd., 3SBio Inc., Reliance Life Sciences, Hisun Pharmaceuticals, Celgen Biopharmaceuticals, Torrent Pharmaceuticals Ltd., Cadila Healthcare Ltd., Shanghai Henlius Biotech Inc., Teva Pharmaceutical Industries Ltd., Alvotech, Xentria Inc., Lazuline Biotech Private Limited, Epygen Biotech Pvt Ltd., Mabpharm Limited, Qilu Pharmaceutical Co. Ltd., Chiatai Tianqing Pharmaceutical Group Co. Ltd., YL Biologics Ltd., Aprogen Biologics, UNDBIO Co Ltd., Samsung Bioepis Co. Ltd., ISU Abxis Corp., Bio-Rad Laboratories Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/biosimilar-monoclonal-antibodie-global-market-report

Which Region Currently Holds The Largest Share Of The Biosimilar Monoclonal Antibodies Market?

North America was the largest region in the biosimilar monoclonal antibodies market in 2025. The regions covered in the biosimilar monoclonal antibodies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Biosimilar Monoclonal Antibodies Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=3412&type=smp

Browse Through More Reports Similar to the Global Biosimilar Monoclonal Antibodies Market 2026, By The Business Research Company

Biologics Market 2026

https://www.thebusinessresearchcompany.com/report/biologics-market

Pharmaceutical Drugs And Biologics Logistics Market 2026

https://www.thebusinessresearchcompany.com/report/pharmaceutical-drugs-and-biologics-logistics-market

Anti Asthmatics And Copd Drugs Market 2026

https://www.thebusinessresearchcompany.com/report/anti-asthmatics-and-copd-drugs-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795